CICS Co., Ltd. (a consolidated subsidiary of Resorttrust, Inc.) Announces Application for Manufacturing and Marketing Approval of Accelerator-based BNCT Treatment System as Medical Device
NQ Score
48/100
N1 Content Completeness
5
AI Summary (NQ-processed)
CICS Co., Ltd., a consolidated subsidiary of Resorttrust, Inc., announced that it has applied for manufacturing and marketing approval for its accelerator-based Boron Neutron Capture Therapy (BNCT) neutron irradiation system, "CICS-1," as of April 30, 2026. This application is based on the results of a domestic Phase II clinical trial for cutaneous angiosarcoma, and due to its designation as an orphan medical device, rapid provision to medical sites is expected.